The Polyarticular Juvenile Idiopathic Arthritis (PJIA) drugs in development market research report provides comprehensive information on the therapeutics under development for Polyarticular Juvenile Idiopathic Arthritis (PJIA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Polyarticular Juvenile Idiopathic Arthritis (PJIA). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Polyarticular Juvenile Idiopathic Arthritis (PJIA) and features dormant and discontinued products.
GlobalData tracks 18 drugs in development for Polyarticular Juvenile Idiopathic Arthritis (PJIA) by 14 companies/universities/institutes. The top development phase for Polyarticular Juvenile Idiopathic Arthritis (PJIA) is preclinical with five drugs in that stage. The Polyarticular Juvenile Idiopathic Arthritis (PJIA) pipeline has 18 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Polyarticular Juvenile Idiopathic Arthritis (PJIA) pipeline products market are: Shilpa Biologicals, JSR Life Sciences and Mycenax Biotech.
The key targets in the Polyarticular Juvenile Idiopathic Arthritis (PJIA) pipeline products market include Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF), Lymphotoxin Alpha (TNF Beta or Tumor Necrosis Factor Ligand Superfamily Member 1 or LTA), and Interleukin 6 Receptor Subunit Alpha (IL6R1 or Membrane Glycoprotein 80 or CD126 or IL6R).
The key mechanisms of action in the Polyarticular Juvenile Idiopathic Arthritis (PJIA) pipeline product include Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF) Inhibitor with 11 drugs in Pre-Registration. The Polyarticular Juvenile Idiopathic Arthritis (PJIA) pipeline products include five routes of administration with the top ROA being Subcutaneous and three key molecule types in the Polyarticular Juvenile Idiopathic Arthritis (PJIA) pipeline products market including Monoclonal Antibody, and Fusion Protein.
Polyarticular Juvenile Idiopathic Arthritis (PJIA) overview
Polyarticular juvenile idiopathic arthritis (PJIA) affects five or more joints. PJIA causes inflammation in the small joints of the fingers and hands, but weight-bearing joints and the jaw can also be affected. Symptoms include fevers, pink rash, eye inflammation, joint pain, joint swelling, and problems with bone development and growth. Treatment includes painkillers, non-steroidal anti-inflammatory drugs (NSAIDs), and disease-modifying anti-rheumatic drugs.
For a complete picture of Polyarticular Juvenile Idiopathic Arthritis (PJIA)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
